Fulvestrant Selective estrogen receptor downregulators (SERDs)

Faslodex - ZM-182780 - ZM 182780 - ICI-182780 - ICI 182780



Trial Studied treatment Control Patients Size Study type Results NCT

Advanced breast cancer (metastatic) - Selective estrogen receptor downregulators (SERDs) in all type of patients - Selective estrogen receptor downregulators (SERDs) in patients recurring or progressing after prior endocrine therapy - Selective estrogen receptor downregulators (SERDs) in first line endocrine therapy

9238UK/0005 (fluvestrant alone)fluvestrant 250mgexemestaneNA NCT00944918
SoFEa (Johnston) fluvestrant alone, 2012fluvestrant 250mgexemestaneNA NCT00253422
CDR0000349337 ongoing fulvestrant + anastrozoleanastrozoleNA NCT00075764
GEICAM/2006-10fulvestrant + anastrozoleanastrozoleNA NCT00543127
FACT (Bergh), 2012fulvestrant + anastrozoleanastrozole514 (258/256) NCT00256698
Mehta(SWOG-S0226), 2012fulvestrant + anastrozoleanastrozoleNA NCT00075764
9238UK/0005 (combination)fulvestrant + anastrozoleexemestaneNA NCT00944918
SoFEa (Johnston) combination, 2012fulvestrant + anastrozoleexemestaneNA NCT00253422
A011106 ongoing fulvestrant 250mganastrozoleNA NCT01953588
Xu et al., 2011fulvestrant 250mganastrozole234 (121/113) NCT00327769
0021 (Osborne), 2002fulvestrant 250mganastrozoleNA NCT00635713
0020 (Howell), 2002fulvestrant 250mganastrozoleNA
EFECT (Chia)fulvestrant 250mgexemestaneNA NCT00065325
9238IL/0025fulvestrant 250mgtamoxifenNA NCT00241449
0025 (Howell), 2004fulvestrant 250mgtamoxifen587 (313/274)
FALCON ongoing fulvestrant 500mganastrozoleNA NCT01602380
FIRST (Robertson), 2010fulvestrant 500mganastrozoleNA NCT00274469
FUMANCE ongoing fulvestrant 500mgcontrolNA NCT02383030
D6997L00021fulvestrant 500mgfulvestrant 250mgNA NCT01300351
CONFIRM (Di Leo), 2010fulvestrant 500mgfulvestrant 250mgNA NCT00099437
FINDER 1 (Ohno), 2010fulvestrant 500mgfulvestrant 250mgNA
FINDER 2, 2010fulvestrant 500mgfulvestrant 250mgNA Exploratory NCT00313170